The expanded collaboration with I-Spy 2 to evaluate Signatera for breast cancer patients could potentially lead to positive outcomes for Natera. If the study yields positive results, it could enhance Natera's reputation and market position in the healthcare sector, potentially leading to an increase in its stock price in the short term.